Clinical trials
Small Cell Lung Cancer Extensive Stage clinical trials
Below are recruiting small cell lung cancer extensive stage clinical trials, each written for real people, not researchers. We’re tracking 190 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07373964RecruitingPhase 2
Study of new drug combo for extensive-stage small-cell lung cancer
This trial tests a new combination of drugs (chidamide, a PD-L1 inhibitor, carboplatin, and etoposide) as the first treatment for people with extensive-stage small-cell lung cancer. The goal is to see if this combination works better than standard treatments.
Shenyang, LiaoningAges 18–75 - NCT07371663RecruitingPhase 1/Phase 2
TCC1727 combination therapy for advanced solid tumors
This trial tests a new drug, TCC1727, combined with other treatments for people with advanced solid tumors that have stopped responding to standard therapy. It aims to see if these combinations can help shrink or control the cancer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07362459RecruitingPhase 3
Study of SCTB14 for untreated advanced non-small cell lung cancer
This trial tests a new drug, SCTB14, as a first treatment for advanced non-small cell lung cancer that has a high level of PD-L1. It aims to see if the drug is safe and effective for people who haven't had other treatments for their cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07354061RecruitingPhase 1/Phase 2
Ensartinib plus chemo before surgery for ALK+ lung cancer
This trial tests whether taking the targeted therapy Ensartinib (which blocks ALK) along with standard chemotherapy before surgery can help shrink ALK-positive lung cancer and improve outcomes. It is for people who have not yet had treatment and whose cancer is at a stage that can be removed with surgery.
Xi’an, ShanxiAges 18–75 - NCT07358676RecruitingPhase 2
Study of bemotuzumab plus chemo and anlotinib for advanced small cell lung cancer
This trial tests a combination of the targeted drug bemotuzumab, chemotherapy, and anlotinib (which blocks blood vessel growth) followed by radiation therapy for people with extensive-stage small cell lung cancer who haven't had treatment yet. The goal is to see if this approach helps control the cancer.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06853678Recruiting
Immunotherapy after first treatment for extensive stage small cell lung cancer
This trial tests immunotherapy drugs for extensive stage small cell lung cancer that has progressed after initial (first-line) chemotherapy. You may be eligible if you have finished standard treatment and your cancer has worsened.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07339059RecruitingPhase 2
Maintenance therapy for advanced small cell lung cancer
This trial tests two immunotherapy drugs (sacituzumab govitecan with atezolizumab or durvalumab) as ongoing treatment to keep extensive-stage small cell lung cancer from progressing. It is for people who have already completed initial chemotherapy and immunotherapy without their cancer getting worse.
Detroit, MichiganAges 18 years+ - NCT06869239Recruiting
Predicting response to PD-L1 inhibitor after chemoradiotherapy for limited-stage small cell lung cancer
This study uses a blood test to see if it can predict how well the PD-L1 inhibitor (an immunotherapy drug) works after standard chemotherapy and radiation for limited-stage small cell lung cancer. It aims to find better ways to match treatment to patients.
Beijing, Beijing MunicipalityAges 18–75 - NCT06663098RecruitingPhase 2
Atezolizumab and chemo again for relapsed small cell lung cancer
This trial tests a combination of a second course of chemotherapy and an immunotherapy drug (atezolizumab) for people with extensive-stage small cell lung cancer that has returned after initial treatment. The goal is to see if re-using these treatments together can help control the cancer again.
Aviano (PN)Ages 18 years+ - NCT07314216RecruitingPhase 2
Firmonertinib plus radiation for stage III lung cancer with rare EGFR mutations
This trial tests whether combining the targeted pill firmonertinib with radiation therapy can help people with stage III non-small cell lung cancer that has certain rare EGFR mutations. It is for those whose cancer cannot be removed by surgery.
Changsha, HunanAges 18 years+ - NCT07291037RecruitingPhase 3
Comparing a new drug to standard chemo for advanced lung cancer
This trial tests a new drug called datopotamab deruxtecan against a standard chemotherapy (docetaxel) for people with a certain type of advanced lung cancer (non-squamous non-small cell lung cancer) that has already been treated. The new drug targets a protein called TROP2 found on cancer cells, which may help slow or stop the cancer's growth.
Chandler, ArizonaAges 18 years+ - NCT07296809RecruitingPhase 2
SKB500 therapy for small cell lung cancer
This trial tests a new drug called SKB500, given alone or with other treatments, for people with extensive-stage small cell lung cancer that has spread. It may be an option for those who have had little or no prior treatment.
Guangzhou, GuangdongAges 18–75 - NCT06717243Recruiting
Study on gene markers in lung cancer for treatment resistance
This study looks at genetic markers in two types of lung cancer (small cell and large cell neuroendocrine) to understand why some tumors stop responding to a standard treatment that combines chemotherapy with immunotherapy. If you have one of these cancers and are about to start this treatment, you may be able to join.
New York, New YorkAges 18–85 - NCT07278479RecruitingPhase 1/Phase 2
Study of a targeted radiation therapy for small cell lung cancer
This trial tests a new drug called MP0712 that delivers radiation directly to cancer cells that have a marker called DLL3. It is for people with small cell lung cancer or other solid tumors that express DLL3, whose cancer has come back after prior treatments.
Tampa, FloridaAges 18 years+ - NCT07244016Recruiting
TCR test to guide immunotherapy and chemo for extensive SCLC
This trial tests whether a blood test (TCR) can help predict how well a combination of the immunotherapy drug tislelizumab and chemotherapy works for people with extensive-stage small cell lung cancer (SCLC) that has not been treated before.
Zhengzhou, HenanAges 18 years+ - NCT07245446RecruitingPhase 2
Ivonescimab for untreated extensive-stage SCLC
This study tests a new immunotherapy drug called ivonescimab for people with extensive-stage small cell lung cancer who have not had treatment before. The goal is to see if it can help shrink tumors and improve survival.
Beijing, Beijing MunicipalityAges 18–75 - NCT07242547RecruitingPhase 2
Tarlatamab maintenance for limited-stage small cell lung cancer
This trial tests a new immunotherapy medicine called tarlatamab given as maintenance therapy after initial treatment for limited-stage small cell lung cancer. It aims to keep the cancer from coming back.
Albacete, AlbaceteAges 18 years+ - NCT07231445RecruitingPhase 1
ZG006 with immunotherapy for extensive small cell lung cancer
This trial tests a new drug, ZG006, combined with standard immunotherapy (PD-1/PD-L1 inhibitors) for people with advanced small cell lung cancer that hasn't been treated before. The goal is to find out if this combination works better than the current standard care.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07226544RecruitingPhase 2
Ivonescimab before surgery for high-risk kidney cancer
This trial tests giving the drug ivonescimab before surgery for patients with high-risk clear cell kidney cancer. The goal is to see if it can help shrink the tumor and improve outcomes.
Duarte, CaliforniaAges 18 years+ - NCT07227597RecruitingPhase 1/Phase 2
Study of two experimental drugs for advanced small cell lung cancer
This study tests two experimental drugs, gocatamig and ifinatamab deruxtecan, for people with advanced small cell lung cancer. The goal is to see if this combination can help control the cancer, either as a first treatment or after initial standard therapy.
Santa Rosa, CaliforniaAges 18 years+ - NCT07226999RecruitingPhase 2/Phase 3
A new study for people with extensive-stage small cell lung cancer using a study drug plus chemo
This trial tests a new study medicine, PF-08634404, combined with chemotherapy for people with extensive-stage small cell lung cancer. It aims to see if this combination works better than standard treatments.
Fayetteville, ArkansasAges 18 years+ - NCT07218146RecruitingPhase 3
Study of ZL-1310 vs Standard Care for Relapsed Small Cell Lung Cancer
This trial tests a new drug, ZL-1310, against standard treatments for people with small cell lung cancer that has returned after initial therapy. The goal is to see if ZL-1310 works better than other options.
La Jolla, CaliforniaAges 18 years+ - NCT07208773RecruitingPhase 1/Phase 2
Study of YL201 and Ivonescimab for advanced solid tumors
This trial tests a new drug combination (YL201 and Ivonescimab) for people with advanced solid tumors that have stopped responding to other treatments. The goal is to see if this combination can shrink tumors or slow their growth.
Guangzhou, GuangdongAges 18 years+ - NCT07203053RecruitingPhase 2
Tarlatamab for advanced small cell lung cancer after first treatment
This trial tests a new drug called tarlatamab for people with advanced small cell lung cancer that has worsened after one prior round of chemotherapy plus immunotherapy. It's designed for patients who are still active but may need extra support (ECOG 2).
AngersAges 18 years+
Hear when a new Small Cell Lung Cancer Extensive Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for small cell lung cancer extensive stage?
- Yes. Clin2 currently lists 190 recruiting small cell lung cancer extensive stage studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a small cell lung cancer extensive stage trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a small cell lung cancer extensive stage trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Extensive-stage Small Cell Lung Cancer (ES-SCLC)
- Extensive Stage Lung Small Cell Cancer
- Non-small Cell Lung Cancer Stage III
- Non Small Cell Lung Cancer
- Limited Stage Small Cell Lung Cancer
- Extensive Stage Lung Small Cell Carcinoma
- Limited-stage Small Cell Lung Cancer (LS-SCLC)
- Stage IIIA Non-small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.